SI1664122T1 - Therapeutic humanised antibodies against cd45 isoforms - Google Patents

Therapeutic humanised antibodies against cd45 isoforms

Info

Publication number: SI1664122T1
Authority: SI; Slovenia
Prior art keywords: isoforms; antibodies against; humanised antibodies; therapeutic; therapeutic humanised
Prior art date: 2003-09-18

Application number

SI200431411T

Other languages

Slovenian (sl)

Inventor

Frank Kolbinger

Herrera Jose M Carballido

Andras Aszodi

Jose W Saldanha

Bruce M Hall

Silvia Gregori

Maria Grazia Roncarolo

Veronique Loux

Gregorio Aversa

Margit Jeschke

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-18

Filing date

2004-09-17

Publication date

2010-07-30

2003-09-18 Priority claimed from US10/666,332 external-priority patent/US20050069538A1/en

2004-06-25 Priority claimed from GB0414309A external-priority patent/GB0414309D0/en

2004-09-17 Application filed by Novartis Ag filed Critical Novartis Ag

2010-07-30 Publication of SI1664122T1 publication Critical patent/SI1664122T1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Obesity (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SI200431411T 2003-09-18 2004-09-17 Therapeutic humanised antibodies against cd45 isoforms SI1664122T1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US10/666,332 US20050069538A1 (en)	2003-09-18	2003-09-18	Therapeutic binding molecules
GB0414309A GB0414309D0 (en)	2004-06-25	2004-06-25	Organic compounds
PCT/EP2004/010471 WO2005026210A2 (en)	2003-09-18	2004-09-17	Therapeutic binding molecules
EP04765363A EP1664122B1 (en)	2003-09-18	2004-09-17	Therapeutic humanised antibodies against cd45 isoforms

Publications (1)

Publication Number	Publication Date
SI1664122T1 true SI1664122T1 (en)	2010-07-30

Family

ID=34315457

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200431411T SI1664122T1 (en)	2003-09-18	2004-09-17	Therapeutic humanised antibodies against cd45 isoforms

Country Status (29)

Country	Link
EP (1)	EP1664122B1 (en)
JP (1)	JP4762142B2 (en)
KR (1)	KR20060079232A (en)
AR (2)	AR045765A1 (en)
AT (1)	ATE461219T1 (en)
AU (1)	AU2004272289B2 (en)
BR (1)	BRPI0414515A (en)
CA (1)	CA2537217A1 (en)
CY (1)	CY1110033T1 (en)
DE (1)	DE602004026081D1 (en)
DK (1)	DK1664122T3 (en)
EC (1)	ECSP066432A (en)
ES (1)	ES2341341T3 (en)
HK (1)	HK1091844A1 (en)
HR (1)	HRP20100334T1 (en)
IL (1)	IL173820A0 (en)
IS (1)	IS8397A (en)
MA (1)	MA28041A1 (en)
MY (1)	MY143963A (en)
NO (1)	NO20061681L (en)
NZ (1)	NZ545605A (en)
PE (1)	PE20060019A1 (en)
PL (1)	PL1664122T3 (en)
PT (1)	PT1664122E (en)
RU (1)	RU2386639C2 (en)
SI (1)	SI1664122T1 (en)
TN (1)	TNSN06087A1 (en)
TW (1)	TW200521231A (en)
WO (1)	WO2005026210A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2502631A1 (en)	2011-03-22	2012-09-26	Medizinische Hochschule Hannover	Immune suppressor and its use
GB201409558D0 (en)	2014-05-29	2014-07-16	Ucb Biopharma Sprl	Method
GB201412658D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
GB201412659D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
CN105886609B (en) *	2015-02-17	2020-02-21	陈沛隆	Method and device for risk assessment of adverse drug reaction
EP4249916A3 (en)	2015-04-06	2023-11-01	President and Fellows of Harvard College	Compositions and methods for non-myeloablative conditioning
GB201601077D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibody molecule
GB201601075D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies molecules
GB201601073D0 (en) *	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies
GB201521393D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
GB201521391D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
GB201521382D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
GB201521389D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Method
GB201521383D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl And Ucb Celltech	Method
WO2017219025A1 (en) *	2016-06-17	2017-12-21	Magenta Therapeutics, Inc.	Compositions and methods for the depletion of cells
EP3630836A1 (en)	2017-05-31	2020-04-08	Elstar Therapeutics, Inc.	Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
IL301859A (en)	2020-10-15	2023-06-01	UCB Biopharma SRL	Binding molecules for CD45 multimerization
AU2021409801A1 (en)	2020-12-21	2023-06-22	Allogene Therapeutics, Inc.	Protease-activating cd45-gate car
WO2023091954A2 (en)	2021-11-19	2023-05-25	The Trustees Of The University Of Pennsylvania	Engineered pan-leukocyte antigen cd45 to facilitate car t cell therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6106834A (en) *	1993-06-02	2000-08-22	Research Corporation Technologies, Inc.	Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
GB0103389D0 (en) *	2001-02-12	2001-03-28	Novartis Ag	Organic compounds

2004
- 2004-09-17 SI SI200431411T patent/SI1664122T1/en unknown
- 2004-09-17 RU RU2006112598/13A patent/RU2386639C2/en not_active IP Right Cessation
- 2004-09-17 ES ES04765363T patent/ES2341341T3/en not_active Expired - Lifetime
- 2004-09-17 TW TW093128255A patent/TW200521231A/en unknown
- 2004-09-17 JP JP2006526599A patent/JP4762142B2/en not_active Expired - Fee Related
- 2004-09-17 MY MYPI20043795A patent/MY143963A/en unknown
- 2004-09-17 EP EP04765363A patent/EP1664122B1/en not_active Expired - Lifetime
- 2004-09-17 PE PE2004000909A patent/PE20060019A1/en not_active Application Discontinuation
- 2004-09-17 PL PL04765363T patent/PL1664122T3/en unknown
- 2004-09-17 CA CA002537217A patent/CA2537217A1/en not_active Abandoned
- 2004-09-17 AT AT04765363T patent/ATE461219T1/en active
- 2004-09-17 DE DE602004026081T patent/DE602004026081D1/en not_active Expired - Lifetime
- 2004-09-17 NZ NZ545605A patent/NZ545605A/en not_active IP Right Cessation
- 2004-09-17 WO PCT/EP2004/010471 patent/WO2005026210A2/en active Application Filing
- 2004-09-17 AR ARP040103362A patent/AR045765A1/en active IP Right Grant
- 2004-09-17 KR KR1020067005352A patent/KR20060079232A/en not_active Application Discontinuation
- 2004-09-17 PT PT04765363T patent/PT1664122E/en unknown
- 2004-09-17 AU AU2004272289A patent/AU2004272289B2/en not_active Ceased
- 2004-09-17 BR BRPI0414515-1A patent/BRPI0414515A/en not_active Application Discontinuation
- 2004-09-17 DK DK04765363.9T patent/DK1664122T3/en active
2006
- 2006-02-20 IL IL173820A patent/IL173820A0/en not_active IP Right Cessation
- 2006-03-14 MA MA28875A patent/MA28041A1/en unknown
- 2006-03-17 EC EC2006006432A patent/ECSP066432A/en unknown
- 2006-03-17 TN TNP2006000087A patent/TNSN06087A1/en unknown
- 2006-04-03 IS IS8397A patent/IS8397A/en unknown
- 2006-04-12 NO NO20061681A patent/NO20061681L/en not_active Application Discontinuation
- 2006-11-09 HK HK06112334.4A patent/HK1091844A1/en unknown
2010
- 2010-05-14 CY CY20101100424T patent/CY1110033T1/en unknown
- 2010-06-10 HR HR20100334T patent/HRP20100334T1/en unknown
- 2010-12-14 AR ARP100104624A patent/AR079458A2/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
RU2006112598A (en)	2007-10-27
AU2004272289B2 (en)	2008-09-18
HRP20100334T1 (en)	2010-07-31
NZ545605A (en)	2009-03-31
RU2386639C2 (en)	2010-04-20
NO20061681L (en)	2006-06-13
PE20060019A1 (en)	2006-02-27
WO2005026210A3 (en)	2005-07-14
CA2537217A1 (en)	2005-03-24
MA28041A1 (en)	2006-07-03
JP2007529196A (en)	2007-10-25
KR20060079232A (en)	2006-07-05
AR079458A2 (en)	2012-01-25
IS8397A (en)	2006-04-03
EP1664122B1 (en)	2010-03-17
ECSP066432A (en)	2006-09-18
DK1664122T3 (en)	2010-06-28
AR045765A1 (en)	2005-11-09
PT1664122E (en)	2010-05-10
TNSN06087A1 (en)	2007-10-03
TW200521231A (en)	2005-07-01
ATE461219T1 (en)	2010-04-15
AU2004272289A1 (en)	2005-03-24
DE602004026081D1 (en)	2010-04-29
ES2341341T3 (en)	2010-06-18
IL173820A0 (en)	2006-07-05
EP1664122A2 (en)	2006-06-07
WO2005026210A2 (en)	2005-03-24
HK1091844A1 (en)	2007-01-26
JP4762142B2 (en)	2011-08-31
BRPI0414515A (en)	2006-11-07
MY143963A (en)	2011-07-29
PL1664122T3 (en)	2010-08-31
CY1110033T1 (en)	2015-01-14

Publication	Publication Date	Title
HK1091844A1 (en)	2007-01-26	Therapeutic humanised antibodies against cd45 isoforms
HK1087131A1 (en)	2006-10-06	Anti-igfr1 antibody therapeutic combinations
EP1572131A4 (en)	2009-07-29	Antibody therapy
IL237756A0 (en)	2015-05-31	Antibody formulations
EP1658095A4 (en)	2006-06-14	De-immunized anti-cd3 antibody
HK1077226A1 (en)	2006-02-10	Human monoclonal antibodies against cd25
GB0416396D0 (en)	2004-08-25	Therapeutic agents
GB0419850D0 (en)	2004-10-13	Therapeutic agents
GB0403780D0 (en)	2004-03-24	Therapeutic agents
EP1682512A4 (en)	2008-03-12	Immunohistochemical methods
IL243687A0 (en)	2016-04-21	Anti-cs1 antibodies for the treatment of multiple myeloma
GB0419192D0 (en)	2004-09-29	Therapeutic agents
GB0400193D0 (en)	2004-02-11	Therapeutic agents
GB0417939D0 (en)	2004-09-15	Therapeutic agents
GB0400196D0 (en)	2004-02-11	Therapeutic agents
GB0416934D0 (en)	2004-09-01	Therapeutic agents
GB0402918D0 (en)	2004-03-17	Therapeutic agents
GB0403779D0 (en)	2004-03-24	Therapeutic agents
GB0325391D0 (en)	2003-12-03	Human monoclonal antibodies
GB0407671D0 (en)	2004-05-05	Therapeutic agents
GB0402525D0 (en)	2004-03-10	Therapeutic agents
GB0406432D0 (en)	2004-04-28	Therapeutic agents
GB0408100D0 (en)	2004-05-12	Therapeutic agents
GB0408101D0 (en)	2004-05-12	Therapeutic agents
GB0408348D0 (en)	2004-05-19	Therapeutic agents